Trial Profile
Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Isoniazid (Primary) ; Rifapentine (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- Acronyms BRIEF-TB
- 10 Mar 2021 Results assessing adverse pregnancy outcomes among women exposed to IPT in a secondary analysis, presented at the 28th Conference on Retroviruses and Opportunistic Infections
- 26 Nov 2020 Results assessing effect of daily 1HP on nevirapine PK in the first 90 participants who enrolled in BRIEF-TB published in the Journal of Antimicrobial Chemotherapy
- 11 Mar 2020 Results assessing geographic and individual risk factors for Tuberculosis or death in the Brief-Tb Trial, presented at the 27th Conference on Retroviruses and Opportunistic Infections